Malvern Instruments and Netzsch Grinding & Dispersing Sign Agreement to Cooperate - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Malvern Instruments and Netzsch Grinding & Dispersing Sign Agreement to Cooperate


UK-based Malvern Instruments and Germany-based Netzsch Grinding & Dispersing have entered into a cooperative marketing agreement for a broad range of market sectors, including pharmaceuticals, announced Netzsch in an April 23 press release.

The global agreement, initially in place for three years, will harness the strength of each company’s brands and unique expertise in materials processing and materials characterization. Under the terms of the agreement, Netzsch will standardize on Malvern’s particle-sizing and characterization equipment, primarily the Mastersizer 3000 laser diffraction particle size analyzer. Customers and prospective customers of each company will gain access both to the extensive milling knowledge of the Netzsch teams and to the particle sizing know-how of Malvern Instruments.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here